Go Deep
Castle Biosciences, Inc.
Castle Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,185 | -51.4 | 2.14 | 0.08 | 3,131.28 |
| Oct 2026 | 19,151 | -51.7 | 2.15 | 0.08 | 3,143.71 |
| Oct 2026 | 19,051 | -52.0 | 2.20 | 0.08 | 3,209.68 |
| Oct 2026 | 19,320 | -49.9 | 2.08 | 0.08 | 3,027.09 |
| Oct 2026 | 19,290 | -50.3 | 2.09 | 0.08 | 3,049.77 |
| Oct 2026 | 19,145 | -51.8 | 2.15 | 0.08 | 3,143.16 |
| Oct 2026 | 18,966 | -53.7 | 2.23 | 0.08 | 3,250.79 |
| Oct 2026 | 19,139 | -51.9 | 2.16 | 0.08 | 3,132.83 |
Castle Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 103,546,000.0 | 83,679,000.0 | 87,010,000.0 | 83,043,000.0 |
| Net Profit | -2,060,000.0 | -14,522,000.0 | -2,332,000.0 | -501,000.0 |
| EPS | -0.1 | -0.5 | -0.1 | -0.0 |
Castle Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 344,229,000.0 | 332,069,000.0 | 219,788,000.0 | 137,039,000.0 | — |
| Net Profit | -24,158,000.0 | 18,245,000.0 | -57,466,000.0 | -67,138,000.0 | — |
| EPS | -0.8 | 0.7 | -2.1 | -2.6 | — |
Castle Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 578,556,000.0 | 531,235,000.0 | 453,340,000.0 | 447,329,000.0 | — |
| Total Liabilities | 107,683,000.0 | 75,400,000.0 | 62,071,000.0 | 48,179,000.0 | — |
| Total Equity | 470,873,000.0 | 455,835,000.0 | 391,269,000.0 | 399,150,000.0 | — |
Owes vs Owns
Castle Biosciences, Inc. owed $0.16 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.16× | 0.19× | 0.14× | 0.14× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Castle Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 51.8%Receivables 7.5%Inventory 1.8%Fixed assets (tangible) 19.4%Intangible assets 17.2%Other assets 2.4%
How it's funded — Dec 2025
Long-term debt 1.7%Payables 3.2%Other liabilities 13.6%Shareholders' equity 81.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 299.5 | 293.1 | 243.1 | 258.6 |
| Receivables | 43.4 | 51.2 | 38.3 | 23.5 |
| Inventory | 10.3 | 8.1 | 7.9 | 4.0 |
| Fixed assets (tangible) | 112.2 | 62.7 | 37.7 | 26.5 |
| Intangible assets | 99.6 | 106.2 | 117.3 | 126.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 13.6 | 9.8 | 8.9 | 8.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.4 | 0.3 | 1.1 | 1.8 |
| Long-term debt | 9.6 | 9.7 | 14.2 | 11.6 |
| Payables | 18.7 | 6.9 | 10.3 | 4.7 |
| Other liabilities | 78.9 | 58.5 | 36.5 | 30.0 |
| Shareholders' equity | 470.9 | 455.8 | 391.3 | 399.1 |
| Net tangible assets | 371.3 | 349.6 | 273.9 | 272.8 |
Castle Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 64,347,000.0 | 64,866,000.0 | -5,626,000.0 | -41,655,000.0 | — |
| Investing Activities | -60,367,000.0 | -50,137,000.0 | -16,183,000.0 | -166,545,000.0 | — |
| Financing Activities | -6,960,000.0 | 6,139,000.0 | -2,298,000.0 | 1,515,000.0 | — |